Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000276:immunology; D002056:Burns / Q000150:complications*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides / Q000276:immunology; D051379:Mice; D011552:Pseudomonas Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides